Europe — EMA
Octanate (Human Coagulation Factor Viii)
Human Coagulation Factor VIII, the active ingredient in Octanate, is a coagulation factor replacement therapy presented as an intravenous solution for intravenous use.
Request sourcing
What is Human Coagulation Factor Viii?
Human Coagulation Factor VIII, the active ingredient in Octanate, is a coagulation factor replacement therapy presented as an intravenous solution for intravenous use. It treats hemophilia A by providing the missing clotting protein in patients with this inherited bleeding disorder. GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.
GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.
What is Human Coagulation Factor Viii used for?
Octanate is a recombinant factor VIII product that acts on the intrinsic pathway of the coagulation cascade, helping : - Hemophilia A (severe): Improves hemostasis by replacing deficient factor VIII and reducing bleeding episodes. - Hemophilia A (moderate) : Provides supplemental factor VIII to support routine prophylaxis. - Hemophilia A (mild ) : Used on‑demand to control bleeding episodes. - Surgical procedures : Facilitates hemostasis during invasive surgeries in patients with hemophilia A. -
